Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 5/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846977 | 0.90 | TRPV1 (0.47) | F3ROCK2ROCK1MAPK1 | |
| SCHEMBL1845815 | 0.88 | F3 (0.54) | F3ROCK2ROCK1HTTRAB9A | |
| SCHEMBL1847099 | 0.87 | LMNA (0.56) | F3ROCK2ROCK1HTTMAPK1 | |
| SCHEMBL1847587 | 0.85 | HTT (0.57) | ROCK1HTTRAB9AKDM4EALDH1A1 | |
| SCHEMBL1849208 | 0.84 | ROCK2 (0.58) | F3ROCK2ROCK1HTTMAPK1 | |
| SCHEMBL4546917 | 0.81 | NAMPT (0.57) | ROCK2ROCK1MAPT | |
| SCHEMBL1849454 | 0.80 | ROCK2 (0.56) | ROCK2ROCK1HTTRAB9A | |
| SCHEMBL1845183 | 0.80 | NAMPT (0.56) | ROCK2ROCK1HTT | |
| SCHEMBL13534571 | 0.80 | ROCK2 (0.54) | F3ROCK2ROCK1HTT | |
| SCHEMBL1847141 | 0.80 | ROCK2 (0.63) | F3ROCK2ROCK1DGAT2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-02 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | disclosed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| EP-2324008-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | F3 1410/4885THRB 2574/4885ROCK2 648/4885 |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | F3 1410/4885THRB 2574/4885ROCK2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.